WINNERS & LOSERS: Ramsdens ups profit view; Reach revenue falls
6th May 2026 10:03
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday. Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday. Read More
ImmuPharma PLC - London-based specialist drug discovery and development company - Chair Tim McCarthy produces open letter to shareholders, noting that resolutions relating to the proposed GBP6 million Lanstead subscription and GBP468,000 WRAP retail offer were approved at the general meeting. Says the fundraise "significantly strengthens our balance sheet and provides the capital required to advance our key strategic priorities." McCarthy adds that ImmuPharma's primary focus remains securing a value-enhancing partnering agreement for lead auto-immune technology platform, P140, this year, as recent progress "continues to reinforce both [its] scientific rationale and commercial positioning," and management is "actively engaged in progressing discussions toward this objective". ImmuPharma is also investing in its "second key asset", type 1 diabetes treatment Kapiglucagon. Says the structure of the Lanstead subscription provides a mechanism to potentially benefit from future share price performance, with an 8 pence benchmark acting as the reference point for returns, meaning that progress on P140 and Kapiglucagon could "support value creation over the period of the [sharing] agreement." Read More
(Alliance News) - ImmuPharma PLC on Friday announced a "supportive response" to its UK patent application for P140, which was itself supported by "positive" study results. Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More
(Alliance News) - Stock prices in London closed mixed on Monday, following dovish remarks from New York Federal Reserve President John Williams and as UK investors wait for the government's latest budget on Wednesday. Read More
(Alliance News) - ImmuPharma PLC on Monday said it is has extended the time-frame for completing a partnership deal for its lead asset P140 to 2026, from the end of 2025. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - The FTSE 100 made steady progress on Monday with a boost from defence stocks and gold miners partially offset by falls in utility stocks. Read More
(Alliance News) - Immupharma PLC on Monday announced the filing of a "groundbreaking" new patent application for its lead asset P140, the world's first immunormalizer. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More
(Alliance News) - European blue-chips opened in the green on Wednesday, after US stocks retreated on Tuesday ahead of US President Donald Trump's tariffs becoming effective on Thursday. Read More
(Alliance News) - ImmuPharma PLC on Monday said its core anti-infective programme with antifungal and antibacterial candidates is progressing through pre-clinical studies, amid a narrowed loss. Read More
(Alliance News) - ImmuPharma PLC on Thursday announced "new discoveries" regarding the mechanism of action of its P140 autoimmune technology platform. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
ImmuPharma PLC - London-based specialist drug discovery and development company - Notes recent movements in its share price, as it has more than multiplied nearly five times higher in the last month to 6.03p per share, from 1.21p. The stock surged 94% higher in a single day in early January, to 2.33p, after ImmuPharma reported breakthrough findings in its preclinical research programme focused on P140 and the pathogenesis of autoimmune diseases. Read More
ImmuPharma PLC - London-based specialist drug discovery and development company - Says its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases has yielded data that provides novel insights into autoimmune mechanisms. P140, the firms lead programme, is a unique non-immunosuppressive peptide for the treatment of systemic lupus erythematosus and chronic idiopathic demyelinating polyneuropathy. Adds that the findings, which were discovered by its R&D subsidiary ImmuPharma Biotech, pave the way for better diagnostics, identifying patients most likely to respond to P140 therapy and improved patient monitoring. Says the research marks a "significant step towards personalised medicine in SLE and other autoimmune diseases." Details of the data findings are not being released at this time since they form part of the ongoing expansion of the firms intellectual property portfolio. Read More